

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB04/005418

International filing date: 30 December 2004 (30.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0400031.1
Filing date: 03 January 2004 (03.01.2004)

Date of receipt at the International Bureau: 31 January 2005 (31.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



PCT/GB2004/005418.



INVESTOR IN PEOPLE


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Andrew Gersey

Dated

19 January 2005





Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference P104573GB
-
2. Patent application number 0400031.1
(The Patent Office will fill in this part)
-
3. Full name, address and postcode of the or of each applicant (underline all surnames) University of Sheffield
Western Bank
SHEFFIELD
S10 2TN
GB
- Patents ADP number (if you know it) 891242002
- If the applicant is a corporate body, give the country/state of its incorporation
-
4. Title of the invention Depression Treatment
-
5. Name of your agent (if you have one) Harrison Goddard Foote
- "Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) 31 St Saviourgate
YORK
YO1 8NQ
- Patents ADP number (if you know it) 07914237002 ✓
-
- | | | | |
|--|---------|---|--|
| 6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number | Country | Priority application number
(if you know it) | Date of filing
(day / month / year) |
|--|---------|---|--|
-
- | | | |
|---|-------------------------------|--|
| 7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application | Number of earlier application | Date of filing
(day / month / year) |
|---|-------------------------------|--|
-
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:
- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d)) yes

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description	13	✓
Claim(s)	5	✓
Abstract	1	✓
Drawing(s)	7	+ 7 RW

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature



Date

2.4.04

12. Name and daytime telephone number of person to contact in the United Kingdom

Rob Doucarty

01904 732120

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Depression Treatment

The invention relates to the treatment of conditions which result in depression, psychosis or a general malaise as a consequence of a disruption in the natural circadian rhythm of cortisol secretion by the adrenal glands of a mammal.

The hormone cortisol, also called the "stress hormone", is secreted by the adrenal glands which are adjacent the kidneys. Cortisol secretion increases when the body is stressed, either physically or psychologically. Hydrocortisone is the most commonly used drug as it is equivalent to cortisol, is rapidly absorbed and is inexpensive. Cortisol is released from the adrenal gland under the regulation of ACTH derived from the pituitary gland (Fig 1). There is a circadian rhythm to cortisol release with high levels first thing in the morning and very low levels around midnight (Fig 2). ACTH and thus cortisol levels begin to rise around 3am and peak at 7am gradually falling over the day to a nadir at midnight (Krieger *et al.*, 1971; Ross *et al.*, 1991).

Conditions which result in depression or a general malaise, are well known. These include, but are not limited to, clinical depression, reactive depression, post-natal depression, depression which results as a consequence of extensive surgery, chronic fatigue, myalgic encephalitis and conditions such as jetlag. Depressive conditions can also be induced by external effects which are self imposed, for example depression can result when a person is either dieting in an effort to lose weight and also when a person is attempting to treat an addiction, for example smoking or cocaine addiction.

25

There are also less serious conditions which result in general malaise, for example shift workers who work unsociable hours can become tired and depressed due to disruption in their normal sleep pattern. It is also known that certain periods of the year induce depression, for example Christmas and Seasonal Affective Disorder (SAD).

30

The physiological effects of depression are varied. However, some general characteristics include, hyperactivity of the hypothalamo-pituitary-adrenal axis resulting in high cortisol levels, loss of the cortisol circadian rhythm and sleep disturbance with early morning waking. High glucocorticoid levels at night-time or at the time of going to sleep may also themselves disturb sleep. It is known that antagonistic drugs that lower cortisol levels alleviate the symptoms of depression. For example corticotrophin releasing factor (CRF), (the hypothalamic hormone that induces ACTH release which in turn induces cortisol release) antagonists have been investigated as potential therapies for depression.

Furthermore, specific antagonists of cortisol activity are known in the art. WO9917779 describes the use of glucocorticoid receptor antagonists to ameliorate psychotic disorders. Cortisol is a glucocorticoid which binds an intracellular glucocorticoid receptor and elevated levels of cortisol, or hypercortisolemia, can be controlled by blocking the activity of the receptor to which cortisol binds. An example of a cortisol receptor antagonist is mifepristone and WO9917779 teaches the use of this antagonist to treat conditions that result from elevated cortisol levels. A further example is described in WO02076390 which teaches the use of glucocorticoid receptor antagonists to treat stress conditions, for example post traumatic stress disorder, in individuals.

In EP1201244 the lowering of elevated cortisol levels is achieved by administration of a composition which alleviates depression and mental stress. The composition comprises a complex of phosphatidyl-L-serine and phosphatidic acid which lowers cortisol and increases serotonin to normal levels.

US2003027802 provides a yet further example of a treatment which alleviates the symptoms of depression which arise as a consequence of weight gain induced by anti-psychotic medications (e.g clozapine, olanzapine, risperidone, quetiapine or sertindole). This is a second medical indication for cortisol receptor antagonists and in particular mifepristone.

What is apparent from the above is that medications which are currently used to treat depression and related disorders are primarily inhibitors of cortisol activity, either directly, or indirectly by blocking receptor activation of a glucocorticoid receptor.

5

In our co-pending application, WO03/015793, we describe the treatment of adrenal dysfunction by the provision of a hydrocortisone composition which has the characteristics of delayed and sustained release and which corrects defects in the circadian release of cortisol. We describe, in the present application, a treatment regime which utilises the delayed and sustained release characteristics of the composition described in WO03/015793 in the treatment of depression and related conditions. The treatment, rather than reduce cortisol or cortisol activity, as is taught in the prior art, produces its effect by returning the patients circadian levels of cortisol to normal by entrainment thereby alleviating the symptoms of depression as a consequence of abnormally high cortisol concentrations.

15

Delivery vehicles which can be used in the working of the invention are known in the art. For example, US 4,261,969, which is incorporated by reference, discloses a polymer composition which is enzyme activated. The composition comprises a sensing means which can detect small amounts of a compound in a complex mixture, for example blood, which is an indicator of the body's need for the drug, and a delivery means which senses the change in the sensing means thereby releasing the drug at a required time in a dose dependent manner. The system is suitable for use in the delivery of a contraceptive drug. A further example is disclosed in EP01077065, which is incorporated by reference. The controlled release formulation comprises a drug core which is surrounded by a release control layer which breaks down after a predetermined delay. EP01077065 also discloses a drug release layer outside the release control layer which provides for an initial rapid release followed by the release of drugs from the drug core. This provides for the delivery of at least two drug doses in a delayed manner.

20

25

30

US 6, 207, 197, which is incorporated by reference, discloses a pharmaceutical composition which is adapted to be retained in the stomach to treat diseases, such as ulcers. These are referred to as gastro-retentive drugs. The invention describes microspheres comprising an inner core containing a therapeutic agent surrounded by a water insoluble polymer which is provided with an outer layer of bioadhesive cationic polymer. The adhesive polymer functions to retain the microsphere in the stomach thereby facilitating the concentrated release of the therapeutic agent in the stomach. EP01053752, which is incorporated by reference, discloses a further example of a preparation which shows controlled release. The preparation comprises two parts, a female and male part, the female part is made from a water insoluble polymer and the male part formed from a composition consisting of ethyl acrylate: methyl methacrylate: trimethylammonioethyl methacrylate co-polymer and a methylacrylic:ethyl acrylate co-polymer. The therapeutic agent is contained within the male and female parts. The formulation is pH sensitive only releasing a therapeutic agent at neutral pH thereby passing through the stomach intact and only releasing in the neutral environment of the small intestine.

WO010957, which is incorporated by reference, discloses an implant which is provided with a coating comprising a polymer matrix which is formed from ethylenically unsaturated monomers which includes a zwitterionic monomer, for example 2-methacryloyloxyethyl-2'-trimethylammoniummethylphosphate salt. The composition absorbs a therapeutically active substance which is then dried by evaporation of the solvent included with the active substance. The implant is then ready for implantation into the patient and begins to slowly release the active substance. US 6, 217, 911, which is incorporated by reference, discloses a controlled release microcapsule for the controlled release of non-steroidal anti-inflammatory drugs for 24 hours to 2 months. The microcapsule is biocompatible and biodegradable and manufactured from DL-lactide-co-glycolide. The composition is topically applied to soft tissues surrounding a surgical incision or wound site. Typically the microspheres are loaded with lidocaine to provide slow release pain relief.

- A yet further example of a delayed release formulation is disclosed in WO02/30398, which is incorporated by reference in its entirety. The formulation comprises a core which includes a drug and a disruption agent and further comprises a regulatory membrane coating on the core formed from a mixture of a water soluble gel-forming polymer and a water -insoluble film-forming polymer. The disruption agent is for example an agent which expands on hydration (e.g. hydroxypropylcellulose, sodium starch glycolate, sodium carboxymethylcellulose, croscarmellose sodium or carbomer). The core includes a spheronisation aid (e.g. microcrystalline cellulose).
- 5 The water soluble gel forming polymer of the regulatory membrane coating is a high viscosity grade hydroxyalkylcellulose (e.g. hydroxypropylmethylcellulose) or a methyl cellulose. The water insoluble film forming polymer of the regulatory membrane coating is an alkyl cellulose (e.g. ethyl cellulose).
- 10
- 15 The invention therefore provides a treatment regime suitable for an animal which comprises the administration of at least hydrocortisone and means which allow for the delayed and sustained release of hydrocortisone.

- According to an aspect of the invention there is provided the use of a combined composition comprising hydrocortisone and a delivery vehicle wherein said delivery vehicle provides for delayed and sustained release of hydrocortisone, for the manufacture of a medicament for use in the treatment of depression or a condition which results in depression, or similar condition.
- 20

- 25 In a preferred embodiment of the invention said depression is clinical depression.

In a further preferred embodiment of the invention said depression is reactive depression.

- 30 In a still further preferred embodiment of the invention said depression is post-natal depression.

In a further preferred embodiment of the invention said condition or malaise is selected from the following group: chronic fatigue syndrome; myalgic encephalitis; jet lag; shift work, depression resulting from a person being overweight; depression
5 resulting from dieting; depression resulting from the treatment of cigarette addiction; depression resulting from the treatment of alcohol addiction; depression resulting from the treatment of drug addiction (e.g. cocaine, heroin); the treatment of seasonal affective disorder or a like condition.

- 10 In a further preferred embodiment of the invention said condition results from the administration of an antipsychotic drug.

In a preferred method of the invention said antipsychotic drug is selected from the group consisting of: clozapine, olanzapine, risperidone, quetiapine or sertindole.

15

When administered, the compositions of the present invention are administered in pharmaceutically acceptable preparations. Such preparations may routinely contain
—pharmaceutically acceptable concentrations of salt, buffering agents, preservatives,
compatible carriers, and optionally other therapeutic agents useful in the treatment of
20 depression or the like.

The composition of the invention can be administered by any conventional route, including injection. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal.

25

The compositions of the invention are administered in effective amounts. An “effective amount” is that amount of a composition that alone, or together with further doses, produces the desired response. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting
30 the progression of the disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods.

The compositions used in the foregoing methods preferably are sterile and contain an effective amount of cortisol/hydrocortisone, glucocorticoid or derivatives thereof for producing the desired response in a unit of weight or volume suitable for administration to a patient. The response can, for example, be monitored by measuring the physiological effects of the composition, such as a decrease of disease symptoms and/or measurement of ACTH and cortisol levels where appropriate. Assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response.

The doses of the composition administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used, the time of dosing and the state of the subject (ie age, sex, weight, body mass index (BMI)). Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, the time of dosing maybe varied and higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits.

In general, doses of the composition are formulated and administered in doses between 1 mg and 30 mg, and preferably between 10mg and 25mg , according to any standard procedure in the art. More preferably still said sustained release composition is administered between 1mg and 30mg at night and between 1 and 15 mg in the morning

An animal as used herein, is a mammal, preferably a human, and including a non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent.

When administered, the compositions of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable

compositions. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare
5 pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like. Also, pharmaceutically-acceptable salts can be
10 prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

The compositions may be combined, if desired, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or
15 more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is
~~combined to facilitate the application. The components of the pharmaceutical~~
compositions also are capable of being co-mingled with the molecules of the present
20 invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

The compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt. The
25 compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods
30 include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are

prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

- 5 Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.
- 10 Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of cortisol/hydrocortisone or functional derivative thereof, which is preferably isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may
15 be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be
20 employed including synthetic mono-or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.
- 25 According to a further aspect of the invention there is provided a method for the treatment of an animal which animal is suffering from, or has a predisposition to depression, or a similar condition, comprising the steps of :
 - i) providing a combined preparation of hydrocortisone, or a functional variant thereof, and a delivery vehicle wherein said vehicle provides for the
30 sustained release of hydrocortisone or variant thereof;

- ii) administering the combined preparation in (i) to an animal requiring treatment such that hydrocortisone, or variant thereof, is released in a sustained manner;
- 5 iii) providing a combined preparation of hydrocortisone, or variant thereof, and a delivery vehicle wherein said vehicle provides for the delayed but sustained release of hydrocortisone, or variant thereof; and
- iv) administering the combined preparation in (iii) to an animal requiring treatment such that hydrocortisone, or variant thereof, is released in a delayed but sustained manner.

10 In a further preferred method of the invention an animal is administered hydrocortisone which is released in a sustained manner which is followed by hydrocortisone which is released in a delayed but sustained manner.

15 In a preferred method of the invention said animal is human.

In a further preferred method of the invention said variant is cortisol or cortisone.

20 In a further preferred method of the invention said condition is selected from the group consisting of: chronic fatigue syndrome; myalgic encephalitis; jet lag; shift work; depression resulting from a person being overweight; depression resulting from a person dieting; depression resulting from the treatment of addiction, for example smoking or drugs (e.g. cocaine, heroine addiction); alcohol addiction; the treatment of seasonal affective disorder or a like condition.

25 In an alternative preferred method of the invention said condition results from the administration of an antipsychotic drug. Preferably said drug is selected from the group consisting of: clozapine, olanzapine, risperidone, quetiapine or sertindole.

30 A patient would take a sustained release preparation in the morning and a night-time preparation which would be a delayed and sustained release formulation. Based on

pharmacokinetic modelling this twice daily administration would reproduce the normal circadian rhythm of, for example, cortisol production.

5 In a further preferred method of the invention said sustained release preparation is administered in the morning, preferably between 08:00 and 12:00.

In a yet further preferred method of the invention said delayed and sustained release formulation is administered in the evening, preferably between 20:00 and 24:00.

10 Moreover the administration of glucocorticoids in a delayed and sustained fashion will minimise the side-effects of glucocorticoids which are predominantly catabolic. Excess glucocorticoids result in increased abdominal fat, wasting of muscle, thin bones and skin, insulin resistance, and low levels of other anabolic hormones including IGF-I and sex steroids such as oestradiol and testosterone. Circadian
15 glucocorticoid therapy will avoid a peak in glucocorticoid levels in the early phase of sleep when the body is fasted and catabolic. The normal build up of cortisol levels occurs prior to waking and by mimicking this circadian rhythm this therapy will prevent the catabolic complications of glucocorticoid therapy. Delayed and sustained glucocorticoid therapy will specifically reduce the deleterious effects of
20 glucocorticoids on bone, skin, muscle, and fat mass.

An embodiment of the invention will now be described by example only and with reference to the following Figures:

25 Figure 1 represents a schematic representation of cortisol regulation in an animal;

Figure 2 represents the normal circadian rhythm of cortisol in an animal;

Figure 3 represents the cortisol profile in a patient taking hydrocortisone three times
30 during a 24 hour period; and

Figure 4 represents a cortisol profile in a patient taking a sustained and a sustained and delayed release composition of hydrocortisone;

Figure 5 illustrates ACTH and cortisol release in a normal individual;

5

Figure 6 illustrates cortisol secretion profile in a normal and depressed individual; and

Figure 7 illustrates the effect of delayed and sustained hydrocortisone on endogenous
10 cortisol levels.

Materials and Methods

Problem in depression

15

Patients with depression have increased cortisol release driven by ACTH and loss of the normal circadian rhythm of cortisol secretion. Cortisol release is entirely dependant on ACTH release from the pituitary. Thus, in the normal individual the release of cortisol parallels that of ACTH (Figure 5).

20

In depressed patients the overall cortisol release is greater and there is a failure of cortisol levels to fall to low levels at night. The profile of a depressed patient compared to a normal individual is illustrated in Figure 6. It is seen that the cortisol area under curve for the depressed patient is increased and the nadir cortisol level is
25 high at midnight.

Treatment of depression

The solution to the problem is to entrain the normal circadian cortisol release. This is
30 achieved by a gradual phase shift in the circadian rhythm of cortisol levels. Delayed and sustained hydrocortisone is given at a time to pre-empt the normal rise in cortisol

levels. Thus, it is possible to switch off endogenous ACTH and cortisol levels. For example in a depressed patient the tablet may be given around, for example, 8pm such that the rise in cortisol levels will occur around midnight and prevent the expected rise in ACTH and cortisol levels at between 2 and 3am. This is
5 illustrated in Figure 7.

Monitoring and entraining the normal circadian rhythm of cortisol in depression

10 Effective treatment will suppress endogenous ACTH and cortisol levels. The effect of treatment will be monitored by measuring the morning ACTH level. When this is suppressed the time of treatment can then be altered to bring the circadian cortisol profile back in phase. To achieve this the tablet of delayed and sustained hydrocortisone may be given later in the evening to allow the rise in cortisol to occur
15 between 2-3am. Again the success of therapy can be monitored by the measurement of ACTH. So the initial phase of treatment is to suppress the endogenous release of cortisol and the second phase is to entrain the normal circadian release of cortisol
—allowing low levels of cortisol at the time of going to sleep with the rise in cortisol levels occurring between 2-3 am and peaking on waking.

20

Shift work and jetlag

Individuals undertaking shift work or moving through time zones do not have a circadian rhythm of cortisol to match their sleep / wake pattern. Thus, they will often
25 attempt to go to sleep with high levels of cortisol and wake with low levels of cortisol and fatigue. The solution is to take delayed and sustained hydrocortisone prior to sleeping. After 24 hours the delayed and sustained hydrocortisone will reinstitute the normal pattern of cortisol release until the sleep / wake cycle is reversed and which time the treatment may be stopped or the individual has
30 established / entrained a new circadian rhythm of cortisol which usually takes 6 weeks.

Claims

1. The use of a combined composition comprising hydrocortisone, or functional variant thereof, and a delivery vehicle wherein said delivery vehicle provides for
5 delayed and sustained release of hydrocortisone, or variant thereof, for the manufacture of a medicament for use in the treatment of depression or a condition which results in depression, or similar condition.
2. Use according to Claim 1 wherein said depression is clinical depression.
10
3. Use according to Claim 1 wherein said depression is reactive depression.
4. Use according to Claim 1 wherein said depression is post-natal depression.
- 15 5. Use according to Claim 1 wherein said condition is selected from the following group: chronic fatigue syndrome; myalgic encephalitis; jet lag; shift work; depression resulting from a person being overweight; depression resulting from dieting; depression resulting from the treatment of cigarette addiction; depression resulting from the treatment of alcohol addiction; depression resulting from the
20 treatment of drug addiction; the treatment of seasonal affective disorder or a like condition.
6. Use according to Claim 1 wherein said condition results from the administration of an antipsychotic drug.
25
7. Use according to Claim 6 wherein said antipsychotic drug is selected from the group consisting of: clozapine, olanzapine, risperidone, quetiapine or sertindole.

8. A method for the treatment of an animal which animal is suffering from, or has a predisposition to depression, or a similar condition, comprising the steps of :

- i) providing a combined preparation of hydrocortisone, or a functional variant thereof, and a delivery vehicle wherein said vehicle provides for the sustained release of hydrocortisone or variant thereof;
- ii) administering the combined preparation in (i) to an animal requiring treatment such that hydrocortisone, or variant thereof, is released in a sustained manner;
- iii) providing a combined preparation of hydrocortisone, or variant thereof, and a delivery vehicle wherein said vehicle provides for the delayed but sustained release of hydrocortisone, or variant thereof; and
- iv) administering the combined preparation in (iii) to an animal requiring treatment such that hydrocortisone, or variant thereof, is released in a delayed but sustained manner.

9. A method according to Claim 8 wherein an animal is administered hydrocortisone which is released in a sustained manner which is followed by hydrocortisone which is released in a delayed but sustained manner.

10. A method according to Claim 8 or 9 wherein said animal is human.

11. A method according to any of Claims 8-10 wherein said functional variant is cortisol or cortisone.

12. A method according to any of Claims 8-11 wherein said condition is clinical depression.

13. A method according to any of Claims 8-11 wherein said condition is reactive depression.

14. A method according to any of Claims 8-11 wherein said condition is post natal depression.

5 15. A method according to any of Claims 8-11 wherein said condition is selected from the group consisting of: chronic fatigue syndrome; myalgic encephalitis; jet lag; shift work; depression resulting from a person being overweight; depression resulting from dieting; depression resulting from the treatment of cigarette addiction; depression resulting from the treatment of alcohol addiction; depression resulting from the treatment of drug addiction; the treatment of seasonal affective disorder or a
10 like condition.

15. A method according to any of Claims 8-11 wherein said condition results from the administration of an antipsychotic drug.

15 16. A method according to Claim 15 wherein said drug is selected from the group consisting of: clozapine, olanzapine, risperidone, quetiapine or sertindole.

17. A method according to any of Claims 8-16 wherein said sustained release preparation is administered in the morning, preferably between 08:00 and 12:00.
20

18. A method according to any of Claims 8-17 wherein said delayed and sustained release formulation is administered in the evening, preferably between 20:00 and 24:00.

25 19. The use of a combined composition comprising a glucocorticoid, and a delivery vehicle wherein said delivery vehicle provides for delayed and sustained release said glucocorticoid for the manufacture of a medicament for use in the treatment of side effects due to the administration of said glucocorticoid.

30

20. Use according to Claim 19 wherein said glucocorticoid is selected from the group consisting of: hydrocortisone or a functional variant thereof; cortisol; cortisone acetate; prednisolone; prednisone; dexamethasone

5 21. Use according to Claim 19 or 20 wherein said side effect is increasing weight gain.

22. Use according to Claim 19 or 20 wherein said side effect is reduction in bone density.

10

23. Use according to Claim 19 or 20 wherein said side effect is muscle or skin wastage.

24. Use according to Claim 19 or 20 wherein said side effect is insulin resistance.

15

25. A method for the treatment of an animal which animal is suffering from side effects as a result of glucocorticoid administration, comprising the steps of :

i) providing a combined preparation of a glucocorticoid and a delivery vehicle wherein said vehicle provides for the sustained release of said glucocorticoid;

20 ii) administering the combined preparation in (i) to an animal requiring treatment such that the glucocorticoid is released in a sustained manner;

iii) providing a combined preparation of a glucocorticoid and a delivery vehicle wherein said vehicle provides for the delayed but sustained release of said glucocorticoid; and

25 iii) administering the combined preparation in (iii) to an animal requiring treatment such that the glucocorticoid is released in a delayed but sustained manner.

26 A method according to Claim 25 wherein said glucocorticoid is selected from
30 the group consisting of: hydrocortisone or a functional variant thereof; cortisol; cortisone acetate; prednisolone; prednisone; dexamethasone.

27. A method according to Claim 25 or 26 wherein said side effect is increasing weight gain.

5 28. A method according to Claim 25 or 26 wherein said side effect is reduction in bone density.

29. A method according to Claim 25 or 26 wherein said side effect is muscle or skin wastage.

10

30. A method according to Claim 25 or 26 wherein said side effect is insulin resistance.

15

20

25

30



Abstract

We describe a treatment regime for the treatment of conditions which result from the
5 abnormal secretion of cortisol.



Figure 1






Figure 2






Figure 3






Figure 4






Fig 5. ACTH and cortisol release in a normal individual






Fig 6. Cortisol profile in normal individual and depressed patient.







Fig 7. Effect of delayed and sustained hydrocortisone on endogenous cortisol levels



THE PATENT OFFICE
21 JAN 2015
Received
International Unit